Prostate-specific antigen velocity before and after elimination of factors that can confound the prostate-specific antigen level

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 3, 2012, Pages 1217-1221

  Park, Jessica J ^a   Chen, Ming Hui ^b   Loffredo, Marian ^a   D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

High risk; Prostate cancer; Prostate cancer management; Prostate cancer specific mortality; PSA velocity

Indexed keywords

PATIENT EDUCATION; PROGNOSTIC SIGNIFICANCE; PROSTATE CANCER; PROSTATE CANCER-SPECIFIC MORTALITY; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN;

ANTIGENS; DIAGNOSIS; DISEASES;

VELOCITY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HIGH RISK PATIENT; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN VELOCITY; VELOCITY;

AGED; BIOPSY; CONFOUNDING FACTORS (EPIDEMIOLOGY); FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 84856408151     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.04.019     Document Type: Article

References (21)

1. A.V. D'Amico, M.H. Chen, K.A. Roehl, and W.J. Catalona Preoperative PSA velocity and risk of death from prostate cancer after radical prostatectomy N Engl J Med 351 2004 125 135
2. A.V. D'Amico, A.A. Renshaw, and B. Sussman Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy JAMA 294 2005 440 447
3. D.A. Patel, J.C. Presit Jr., and J.E. McNeal Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy J Clin Oncol 23 2005 6157 6162
4. P.J. Rossi, J. Urbanic, and P.E. Clark Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone Brachytherapy 7 2008 286 289
5. D. Palma, S. Tyldesley, T. Pickles Prostate Cohort Outcomes Initiative Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy Cancer 112 2008 1941 1948
6. A.V. D'Amico, M.H. Chen, and A.A. Renshaw Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer J Urol 176 2006 S11 S15
7. M. Gleave, and W.K. Kelly High-risk localized prostate cancer: A case for early chemotherapy J Clin Oncol 23 2005 8186 8191
8. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974
9. A.J. Stephenson, P.T. Scardino, and J.A. Eastham Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Natl Cancer Inst 98 2006 715 717
10. J.A. Eastham, E.P. Christopher, and A. Zeitman What is the optimal management of high risk, clinically localized prostate cancer? Urol Oncol 28 2010 557 567
11. O. Yossepowitch, E.E. Scott, and A.M. Serio Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy Eur Urol 53 2008 950 959
12. P. Modi, B.T. Helfand, and K.T. McVary Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen Curr Urol Rep 11 2010 224 227
13. X. Yu, S.P. Elliott, and T.J. Wilt Practice patterns in benign prostatic hyperplasia surgical therapy: The dramatic increase in minimally invasive technologies J Urol 180 2008 241
14. J.A. Eastham, E. Riedel, and P.T. Scardino Variation of serum prostate-specific antigen levels: An evaluation of year-to-year fluctuations JAMA 289 2003 2695 2700
15. M.F. O'Brien, A.M. Cronin, and P.A. Fearn Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively Int J Cancer 128 10 2011 2373 2381
16. L. Nogueira, R. Corradi, and J.A. Eastham Prostatic specific antigen for prostate cancer detection Int Braz J Urol 35 2009 521
17. S.L. Chang, L.C. Harshman, and J.C. Presti Impact of common medications on serum total prostate-specific antigen levels: Analysis of the National Health and Nutrition Examination Survey J Clin Oncol 28 2010 3951 3957
18. M.H. Kutner, C.J. Nachtsheim, J. Neter, and W. Li Applied Linear Statistical Models (5th ed.). Part 1: Simple Linear Regression 2004 McGraw-Hill/Irwin Boston p 2-212
19. A. Agresti Categorical Data Analysis 2nd ed. 2002 Wiley New York p 70-114
20. R.G. Nixon, M.H. Wener, and K.M. Smith Biological variation of prostate specific-antigen levels in serum: An evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients J Urol 157 1997 2183 2190
21. D.K. Ornstein, D.S. Smith, and G.S. Rao Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers J Urol 157 1997 2179 2182